A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Authors
Jonker, D JRosen, L S
Sawyer, M B
de Braud, F
Wilding, G
Sweeney, C J
Jayson, Gordon C
McArthur, G A
Rustin, G
Goss, G
Kantor, J
Velasquez, L
Syed, S
Mokliatchouk, O
Feltquate, D M
Kollia, G
Nuyten, D S A
Galbraith, S
Affiliation
Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada.Issue Date
2011-06
Metadata
Show full item recordAbstract
This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.Citation
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. 2011, 22 (6):1413-9 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdq599PubMed ID
21131369Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdq599